Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial.

Signe Møller-Bisgaard,Kim Hørslev-Petersen,B Ejbjerg,Merete Lund Hetland,René dePont Christensen,Lykke Midtbøll Ørnbjerg,Daniel Glinatsi,Jakob M. Møller,Morten Ilum Boesen,Kristian Stengaard-Pedersen,Ole Rintek Madsen,Bente Jensen,Jan Alexander Villadsen,Ellen Margrethe Hauge,Philip Bennett,Oliver Hendricks,Karsten Asmussen,Marcin Ryszard Kowalski,Hanne Merete Lindegaard,Henning Bliddal,Niels Steen Krogh,Torkell Ellingsen,A. H. Nielsen,L Larsen,A.G. Jurik,H.S. Thomsen,Mikkel Østergaard

Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial.

2021

Objectives: To compare the effect of treat-to-target-based escalations in conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologics on clinical disease activity and magn...

Keywords:

MEDLINE
Antirheumatic drugs
clinical disease
Rheumatoid arthritis
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations